AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11425979 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PPP and PVP imaging
Number of subjects: 77
Study 11425979 — intervention group
Group type: COMPARATOR
Intervention: Arterial phase (AP) imaging
Number of subjects: 77
Study 9504575 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger changed every 24 hours
Number of subjects: 29
Study 9504575 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger changed every 48 hours
Number of subjects: 29
Study 9504575 — intervention group
Group type: COMPARATOR
Intervention: Heated humidifier system changed every 48 hours
Number of subjects: 29
Study 8109895 — intervention group
Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation (TLI)
Number of subjects: 30
Study 8109895 — intervention group
Group type: COMPARATOR
Intervention: Sham radiation (Control)
Number of subjects: 30
Study 3294371 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice powder-based ORS
Number of subjects: 60
Study 30358109 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (anti-TNF antibody)
Number of subjects: 0
Study 30358109 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavrilimumab (GM-CSF receptor antibody)
Number of subjects: 0
Study 30358109 — intervention group
Group type: COMPARATOR
Intervention: Golimumab
Number of subjects: 0
Study 30358109 — intervention group
Group type: COMPARATOR
Intervention: Mavrilimumab
Number of subjects: 0
Study 28546090 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabotegravir (800 mg intramuscular injections every 12 weeks)
Number of subjects: 127
Study 28546090 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline injections every 12 weeks)
Number of subjects: 127
Study 28546090 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabotegravir (800 mg intramuscular injections)
Number of subjects: 127
Study 25705822 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut consumption until 60 months of age
Number of subjects: 640
Study 25705822 — intervention group
Group type: COMPARATOR
Intervention: Peanut avoidance until 60 months of age
Number of subjects: 640
Study 24107588 — intervention group
Group type: EXPERIMENTAL
Intervention: CXL-1020 (50-500 μmol/L)
Number of subjects: 0
Study 24107588 — intervention group
Group type: EXPERIMENTAL
Intervention: CXL-1020
Number of subjects: 0
Study 21190995 — intervention group
Group type: EXPERIMENTAL
Intervention: Partly self-administered exercise intervention
Number of subjects: 105
Study 21190995 — intervention group
Group type: COMPARATOR
Intervention: Social contact control group
Number of subjects: 105
Study 19058981 — intervention group
Group type: EXPERIMENTAL
Intervention: HES200/0.62
Number of subjects: 62
Study 19058981 — intervention group
Group type: EXPERIMENTAL
Intervention: HES130/0.4
Number of subjects: 62
Study 19058981 — intervention group
Group type: COMPARATOR
Intervention: gelatine
Number of subjects: 62
Study 17005076 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 128
Study 17005076 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 128
Study 17005076 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with Chinese medicine (Synthetic group)
Number of subjects: 128
Study 12789623 — intervention group
Group type: EXPERIMENTAL
Intervention: LY-354740
Number of subjects: 0
Study 10386759 — intervention group
Group type: COMPARATOR
Intervention: Hypothermia (28 degrees C)
Number of subjects: 66
Study 10386759 — intervention group
Group type: COMPARATOR
Intervention: Moderate hypothermia (32 degrees C)
Number of subjects: 66
Study 10386759 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (37 degrees C)
Number of subjects: 66
Study 8767945 — intervention group
Group type: EXPERIMENTAL
Intervention: Agee endoscopic procedure
Number of subjects: 120
Study 8767945 — intervention group
Group type: COMPARATOR
Intervention: Conventional open procedure
Number of subjects: 120
Study 1898697 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy (0.2 mg/kg per day)
Number of subjects: 0
Study 1898697 — intervention group
Group type: COMPARATOR
Intervention: Hyperinsulinemic clamp (insulin concentration > 1435 pmol/L)
Number of subjects: 0
Study 6849746 — intervention group
Group type: COMPARATOR
Intervention: i.v. nicardipine (0.5-20 mg)
Number of subjects: 10
Study 6849746 — intervention group
Group type: COMPARATOR
Intervention: Oral nicardipine (10-40 mg)
Number of subjects: 10
Study 6849746 — intervention group
Group type: COMPARATOR
Intervention: 40 mg nicardipine
Number of subjects: 10
Study 6849746 — intervention group
Group type: COMPARATOR
Intervention: 20 mg nifedipine
Number of subjects: 10
Study 31344451 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (HCT)
Number of subjects: 380
Study 31344451 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo-naivety before HCT
Number of subjects: 380
Study 31344451 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute graft-versus-host disease (aGVHD) grades II to IV
Number of subjects: 380
Study 31344451 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotherapy
Number of subjects: 380
Study 31344451 — intervention group
Group type: COMPARATOR
Intervention: Immune profiles of total absolute lymphocytes
Number of subjects: 380
Study 31344451 — intervention group
Group type: EXPERIMENTAL
Intervention: CD3-CD16+CD56+ natural killer cells, CD3+ T cells, CD3+CD4+ T cell subset, and CD3+CD8+ T cell subset
Number of subjects: 380
Study 31344451 — intervention group
Group type: COMPARATOR
Intervention: Overall survival
Number of subjects: 380
Study 31344451 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased levels of IgM, IgA, and IgG
Number of subjects: 380
Study 30859995 — intervention group
Group type: EXPERIMENTAL
Intervention: AR19 (20-mg capsule)
Number of subjects: 36
Study 30859995 — intervention group
Group type: COMPARATOR
Intervention: Reference (2 x 10-mg tablets)
Number of subjects: 36
Study 30859995 — intervention group
Group type: EXPERIMENTAL
Intervention: AR19
Number of subjects: 36
Study 30859995 — intervention group
Group type: COMPARATOR
Intervention: Reference
Number of subjects: 36
Study 28490225 — intervention group
Group type: EXPERIMENTAL
Intervention: Short arm plaster cast
Number of subjects: 0
Study 28490225 — intervention group
Group type: COMPARATOR
Intervention: Long arm plaster cast
Number of subjects: 0
Study 25183475 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based decision aid
Number of subjects: 1253
Study 25183475 — intervention group
Group type: EXPERIMENTAL
Intervention: Print-based decision aid
Number of subjects: 1253
Study 23886675 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 134
Study 23886675 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 134
Study 21474638 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-augmented balance training
Number of subjects: 42
Study 21474638 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional balance training (CB)
Number of subjects: 42
Study 21474638 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained)
Number of subjects: 42
Study 17909087 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg once daily for 6 weeks
Number of subjects: 22
Study 16836626 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (n = 279)
Number of subjects: 553
Study 16836626 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 274)
Number of subjects: 553
Study 15758248 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with coronary atherosclerosis
Number of subjects: 67
Study 15758248 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with three-vessel coronary artery disease
Number of subjects: 67
Study 15758248 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin plasma level
Number of subjects: 67
Study 15758248 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy men)
Number of subjects: 67
Study 10880411 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty/placebo
Number of subjects: 0
Study 10880411 — intervention group
Group type: COMPARATOR
Intervention: Stent/placebo
Number of subjects: 0
Study 10880411 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty/abciximab
Number of subjects: 0
Study 10880411 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent/abciximab
Number of subjects: 0
Study 8720432 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) infusion at 1, 10, and 100 ng/min/dl forearm volume
Number of subjects: 15
Study 8720432 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 15
Study 8720432 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) infusion
Number of subjects: 15
Study 1633010 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (PN)
Number of subjects: 38
Study 1633010 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (PN) plus biosynthetic human growth hormone (bGH) 4 UI/daily
Number of subjects: 38
Study 6565306 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterbed
Number of subjects: 15
Study 6565306 — intervention group
Group type: COMPARATOR
Intervention: Foam
Number of subjects: 15
Study 6565306 — intervention group
Group type: COMPARATOR
Intervention: Standard mattresses
Number of subjects: 15
Study 3534588 — intervention group
Group type: EXPERIMENTAL
Intervention: One cycle of CMF chemotherapy (cyclophosphamide, methotrexate, and 5-fluorouracil) preoperatively
Number of subjects: 98
Study 3534588 — intervention group
Group type: COMPARATOR
Intervention: Postoperative adjuvant chemotherapy (not specified in detail)
Number of subjects: 98
Study 31471752 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation tool for planning and predicting RFA zones
Number of subjects: 45
Study 29325658 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-Motivational Interviewing (MI)
Number of subjects: 29
Study 29325658 — intervention group
Group type: COMPARATOR
Intervention: Nonusers
Number of subjects: 29
Study 27695785 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% linseed oil (LO)
Number of subjects: 12
Study 27695785 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% linseed oil and 2% malate (LOM)
Number of subjects: 12
Study 24185690 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative functional hand-based splint
Number of subjects: 30
Study 24185690 — intervention group
Group type: COMPARATOR
Intervention: Standard spica splint
Number of subjects: 30
Study 22033034 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) chemotherapy with cisplatin/paclitaxel
Number of subjects: 454
Study 22033034 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal (IP) chemotherapy with carboplatin followed by cisplatin/paclitaxel
Number of subjects: 454
Study 22033034 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with low pre-chemotherapy CA125 levels
Number of subjects: 454
Study 20088995 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard intervention sent centrally at 1, 2, 3, 4, and 5 months after discharge
Number of subjects: 0
Study 20088995 — intervention group
Group type: COMPARATOR
Intervention: Three trial-specific assessments (baseline, 3- and 6-month assessments)
Number of subjects: 0
Study 20088995 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard intervention
Number of subjects: 0
Study 19039946 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaza (superlow-dose antibodies to endothelial NO synthase)
Number of subjects: 0
Study 19039946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15717335 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine cognitive intervention (videoconferencing)
Number of subjects: 22
Study 15717335 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face cognitive intervention
Number of subjects: 22
Study 12775314 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate 0.05% cream
Number of subjects: 3500
Study 11593504 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg daily
Number of subjects: 429
Study 11593504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study 8911885 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium tiludronate 200 mg
Number of subjects: 40
Study 8911885 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium tiludronate 400 mg
Number of subjects: 40
Study 8911885 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium tiludronate 600 mg
Number of subjects: 40
Study 8911885 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium tiludronate 800 mg
Number of subjects: 40
Study 8911885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1874095 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.3 mg/kg)
Number of subjects: 6
Study 1874095 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.3 mg/kg)
Number of subjects: 6
Study 1874095 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone (5 mg/kg)
Number of subjects: 6
Study 6344138 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 40
Study 6344138 — intervention group
Group type: COMPARATOR
Intervention: Renografin‐60 (meglumine diatrizoate)
Number of subjects: 40
Study 31608454 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukoreduced (LR) RBCs
Number of subjects: 0
Study 31608454 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard unmodified (STD) RBCs
Number of subjects: 0
Study 31608454 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukoreduced and γ‐irradiated (LRγ) RBCs
Number of subjects: 0
Study 31608454 — intervention group
Group type: COMPARATOR
Intervention: Nontransfused patients
Number of subjects: 0
Study 28159539 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 25 mg
Number of subjects: 200
Study 28159539 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 1.5 mg
Number of subjects: 200
Study 27635065 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathology tissue specimens for prostate cancer
Number of subjects: 4340
Study 27635065 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathology tissue specimens for lung cancer
Number of subjects: 4340
Study 27635065 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathology tissue specimens for colorectal cancer
Number of subjects: 4340
Study 27635065 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathology tissue specimens for adenoma
Number of subjects: 4340
Study 27635065 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathology tissue specimens for ovarian cancer and borderline tumors
Number of subjects: 4340
Study 27635065 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathology tissue specimens for breast cancer
Number of subjects: 4340
Study 27635065 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathology tissue specimens for bladder cancer
Number of subjects: 4340
Study 24993764 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioflupane ((123)I)
Number of subjects: 928
Study 22159910 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP-32 (3 pmol kg(‐1) min(‐1) intravenously for 4 hours)
Number of subjects: 10
Study 22159910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 22159910 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP-32
Number of subjects: 10
Study 20565296 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccine
Number of subjects: 118
Study 20565296 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vitamin B injections)
Number of subjects: 118
Study 17656607 — intervention group
Group type: EXPERIMENTAL
Intervention: Triage liaison physician (TLP) shifts
Number of subjects: 14
Study 17656607 — intervention group
Group type: COMPARATOR
Intervention: Control shifts
Number of subjects: 14
Study 16274597 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated injector (Softinject)
Number of subjects: 300
Study 16274597 — intervention group
Group type: COMPARATOR
Intervention: Conventional syringe
Number of subjects: 300
Study 11766999 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20-40 mg/day)
Number of subjects: 179
Study 11766999 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (75-150 mg/day)
Number of subjects: 179
Study 11766999 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 179
Study 11766999 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 179
Study 9159676 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear corneal incision
Number of subjects: 100
Study 9159676 — intervention group
Group type: COMPARATOR
Intervention: Scleral tunnel incision
Number of subjects: 100
Study 7934151 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline via Turbuhaler (1.0 mg)
Number of subjects: 15
Study 7934151 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline via Turbuhaler (2.5 mg)
Number of subjects: 15
Study 7934151 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline via CFC inhaler (1.0 mg without Nebuhaler)
Number of subjects: 15
Study 7934151 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline via CFC inhaler (2.5 mg with Nebuhaler)
Number of subjects: 15
Study 7934151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3073868 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (Wellferon) at doses of 5 MU/m2 i.m. daily for the first 4 weeks and three times weekly for 5 months thereafter
Number of subjects: 70
Study 3073868 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 3073868 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (Wellferon)
Number of subjects: 70
Study 30553700 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of RG7800
Number of subjects: 0
Study 27650320 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-but not Alone mobile health application educational programme
Number of subjects: 118
Study 27650320 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 118
Study 25154701 — intervention group
Group type: EXPERIMENTAL
Intervention: BodyPump™ training (PUMP)
Number of subjects: 68
Study 25154701 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 68
Study 23891224 — intervention group
Group type: EXPERIMENTAL
Intervention: cobas® 4800 assay
Number of subjects: 921
Study 23891224 — intervention group
Group type: EXPERIMENTAL
Intervention: m2000 real-time™ assay
Number of subjects: 921
Study 21114770 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion-SR 150 mg/day for 2 months
Number of subjects: 19
Study 21114770 — intervention group
Group type: COMPARATOR
Intervention: Control group (19 healthy men)
Number of subjects: 19
Study 19646565 — intervention group
Group type: COMPARATOR
Intervention: Emergency contraception (recent use)
Number of subjects: 718
Study 19646565 — intervention group
Group type: COMPARATOR
Intervention: Emergency contraception (ever having used)
Number of subjects: 718
Study 16462011 — intervention group
Group type: EXPERIMENTAL
Intervention: SampEn
Number of subjects: 11
Study 16462011 — intervention group
Group type: EXPERIMENTAL
Intervention: SpecEn
Number of subjects: 11
Study 16462011 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched)
Number of subjects: 11
Study 14625752 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic GBP
Number of subjects: 58
Study 14625752 — intervention group
Group type: COMPARATOR
Intervention: Open GBP
Number of subjects: 58
Study 14625752 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study 11406908 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 580
Study 11406908 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 580
Study 9133884 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact with a stroke family care worker
Number of subjects: 417
Study 9133884 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 417
Study 7700071 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (2.5-5 mg, once daily for 12 weeks)
Number of subjects: 114
Study 7700071 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (10-20 mg, once daily for 12 weeks)
Number of subjects: 114
Study 7700071 — intervention group
Group type: COMPARATOR
Intervention: Cilazapril
Number of subjects: 114
Study 7700071 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine
Number of subjects: 114
Study 7700071 — intervention group
Group type: COMPARATOR
Intervention: Cilazapril and Nitrendipine
Number of subjects: 114
Study 3428344 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofepramine (140 mg)
Number of subjects: 6
Study 3428344 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (50 mg)
Number of subjects: 6
Study 3428344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31853543 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning (ML)
Number of subjects: 1912
Study 31853543 — intervention group
Group type: COMPARATOR
Intervention: ASCVD-risk and CAC measures
Number of subjects: 1912
Study 31853543 — intervention group
Group type: COMPARATOR
Intervention: Systolic blood pressure and cholesterol
Number of subjects: 1912
Study 30075596 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiological study (ES) positive, treated by catheter ablation and/or device implants
Number of subjects: 72
Study 30075596 — intervention group
Group type: COMPARATOR
Intervention: Electrophysiological study (ES) negative, no interventional treatment
Number of subjects: 72
Study 27206810 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine/isosorbide dinitrate (HYIS) 50 mg/20 mg t.i.d. for 24 weeks
Number of subjects: 147
Study 27206810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 27206810 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine/isosorbide dinitrate (HYIS)
Number of subjects: 147
Study 25782469 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.25 g SMO.IR and placebo alcohol preparation
Number of subjects: 24
Study 25782469 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.25 g SMO.IR and alcohol
Number of subjects: 24
Study 25782469 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.25 g SMO.IR matching placebo and alcohol
Number of subjects: 24